HM

Hubert Metzner

CA Csl Behring Ag: 11 patents #4 of 160Top 3%
CL Csl Limited: 7 patents #12 of 176Top 7%
AG Aventis Behring Gmbh: 4 patents #7 of 87Top 9%
CA Csl Behring Lengnau Ag: 3 patents #5 of 30Top 20%
ZA Zlb Behring Ag: 3 patents #1 of 41Top 3%
Overall (All Time): #136,917 of 4,157,543Top 4%
28
Patents All Time

Issued Patents All Time

Showing 25 most recent of 28 patents

Patent #TitleCo-InventorsDate
11814421 Truncated von Willebrand Factor polypeptides for treating hemophilia Stefan Schulte, Thomas Weimer, Sabine Pestel, Steve Dower 2023-11-14
11554156 Pharmaceutical formulations of C1 esterase inhibitor Ernst-Juergen Kanzy 2023-01-17
11510968 Method for improving the stability of purified Factor VIII after reconstitution Carsten Horn, Sabine Zollner, Stefan Schulte 2022-11-29
11479578 Protein purification and virus inactivation with alkyl glycosides Tobias BRANDT, Carsten Horn, Thomas Nowak 2022-10-25
10881717 Method for improving the stability of purified Factor VIII after reconstitution Carsten Horn, Sabine Zollner, Stefan Schulte 2021-01-05
10688157 Truncated von Willebrand factor polypeptides for treating hemophilia Stefan Schulte, Sabine Pestel, Thomas Weimer 2020-06-23
10537616 Method for improving the stability of purified factor VIII after reconstitution Carsten Horn, Sabine Zollner, Stefan Schulte 2020-01-21
10238718 Factor VIII formulation Uwe Liebing, Christina Bodenbender 2019-03-26
9956269 Method for improving the stability of purified factor VIII after reconstitution Carsten Horn, Sabine Zollner, Stefan Schulte 2018-05-01
9878017 Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto Stefan Schulte, Thomas Weimer 2018-01-30
9511123 Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII Sabine Zollner 2016-12-06
9393289 Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII Sabine Zollner 2016-07-19
9394353 Method for improving the stability of purified factor VIII after reconstitution Carsten Horn, Sabine Zollner, Stefan Schulte 2016-07-19
9290561 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life Thomas Weimer, Stefan Schulte, Ulrich Kronthaler, Holger Lind, Wiegand Lang 2016-03-22
8754194 Modified coagulation factors with prolonged in vivo half-life Stefan Schulte, Thomas Weimer 2014-06-17
8575104 Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life Thomas Weimer, Stefan Schulte, Ulrich Kronthaler, Holger Lind, Wiegand Lang 2013-11-05
8012728 Thrombin preparations and process for their production Heinrich Scheider 2011-09-06
7939288 Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques Erhardt Wrabetz, Wolfgang Korte 2011-05-10
7939632 Proteolytically cleavable fusion proteins with high molar specific activity Thomas Weimer, Stefan Schulte 2011-05-10
7550567 Fibrinogen purification Uwe Liebing, Annette Feussner, Joerg Lemmer, Stefan Schulte, Volker Gawantka 2009-06-23
7351561 Thrombin preparations and process for their production Heinrich Scheider 2008-04-01
7276235 Tissue glue with improved antiadhesive properties Peter Gronski, Gerhard Dickneite, Monika Kroez 2007-10-02
7045601 Storage-stable, liquid fibrinogen formulation Uwe Liebing, Gerhardt Kumpe, Stefan Schulte, Volker Gawantka, Karlheinz Enssle 2006-05-16
6874657 Biological sealant storage and dispensing system Stewart Fox 2005-04-05
6790410 Use of a hydrogen peroxide plasma sterilization method for the mild sterilization of temperature-sensitive products Joerg Lemmer, Horst Naumann 2004-09-14